Digital pathology Opportunity to expand collaboration with Artera integration enabling rapid sharing of biopsy slide images and near real-time result delivery, which can streamline clients’ workflow and reduce turnaround times.

Strategic partnerships Recent partnerships with Azer Scientific for digital pathology hardware and Lumea for viewer solutions indicate a channel-ready path to upsell digital pathology platforms, scanners, and integrated viewing tools to current and new clients.

Expanded test menu Introduction of advanced panels such as BioFire GI Panel and ongoing FISH capabilities position Acupath to cross-sell specialized molecular and infectious disease tests to urology, GI, oncology, and gastroenterology practices.

Scale and reach With a sizeable client base and annual specimen volume, there is potential to target mid-market hospitals and regional labs seeking sub-specialized pathology services, MPI-driven cost efficiencies, and standardized report delivery.

Covid response legacy Acupath’s FDA EUA compliant rapid testing capability for COVID-19 demonstrates a capacity for rapid deployment and compliance-driven testing services that could be re-leveraged for seasonal outbreaks or new infectious disease panels.